Spero Therapeutics Inc. Registered Shares DL -,001
- BID
1.135
- ASK
1.179
- 17,621 Units3,250 Units
- 07/23, 11:44:04 AM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
45.50%
Market Cap
-
P/E Ratio
16.05
Dividend Yield
0.00 %
Earnings per Share
0.13 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 1.135 G | 0 Units |
| PRICE DETERMINATION TIME | 07/23/2026 / 11:31:39 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 1.155 | 1.079 |
| PREV. DAY'S PRICE | 1.101 | (07/22) |
| CHANGE DAY BEFORE | +0.03 | 3.09 % |
| 52 WEEK HIGH / LOW | 2.604 (05/27) | 1.093 (07/22) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 0.40 | -1.17 | 0.13 | -0.25 | 0.59 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 3.42 | - | 16.05 | - | 2.06 |
PRICE - BOOK RATIO | 0.73 | 1.22 | 2.23 | - | - |
PRICE - SALES RATIO | 0.81 | 2.03 | 2.31 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A2H63F |
| ISIN | US84833T1034 |
| SYMBOL | 2HA |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | SPERO THERAP.INC. DL-,001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -24.28 % | -42.45 % | -54.35 % | -46.55 % | -45.50 % | -14.72 % | -91.12 % | -42.24 % |
| HIGH | 1.45 | 2.02 | 2.60 | 2.60 | 2.60 | 2.60 | 16.60 | 2.60 |
| LOW | 1.09 | 1.09 | 1.09 | 1.09 | 1.09 | 0.49 | 0.49 | 1.09 |
Dividende
pro Aktie
SPERO THERAP.INC. DL-,001 does not deliver dividend information
Company profile
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.